Drug Screening Model Meets Cancer Organoid Technology

Overview

Journal Transl Oncol

Specialty Oncology

Date 2020 Aug 22

PMID 32822897

Citations 26

Authors

Chen Liu

Tianyu Qin

Yuhan Huang

Yuan Li

Gang Chen

Chaoyang Sun

Affiliations

Soon will be listed here.

Abstract

Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.

Citing Articles

Engineering the 3D structure of organoids.

Moss S, Bakirci E, Feinberg A Stem Cell Reports. 2024; 20(1):102379.

PMID: 39706178 PMC: 11784486. DOI: 10.1016/j.stemcr.2024.11.009.

Application and prospect of organoid technology in breast cancer.

Huang S, Mei Z, Wan A, Zhao M, Qi X Front Immunol. 2024; 15:1413858.

PMID: 39253075 PMC: 11381393. DOI: 10.3389/fimmu.2024.1413858.

Research progress on the application of organoids in gynecological tumors.

Shen Y, Wang Y, Wang S, Li C, Han F Front Pharmacol. 2024; 15:1417576.

PMID: 38989138 PMC: 11234177. DOI: 10.3389/fphar.2024.1417576.

Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.

Yokota E, Iwai M, Ishida Y, Yukawa T, Matsubara M, Naomoto Y Hum Cell. 2024; 37(4):1132-1140.

PMID: 38829559 PMC: 11194197. DOI: 10.1007/s13577-024-01085-8.

Chronotoxici-Plate Containing Droplet-Engineered Rhythmic Liver Organoids for Drug Toxicity Evaluation.

Zhou J, Huang Y, Wang W, Li J, Hou Y, Yi Z Adv Sci (Weinh). 2024; 11(28):e2305925.

PMID: 38720476 PMC: 11267367. DOI: 10.1002/advs.202305925.

References

Sato T, Vries R, Snippert H, van de Wetering M, Barker N, Stange D . Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009; 459(7244):262-5. DOI: 10.1038/nature07935. View

Broutier L, Andersson-Rolf A, Hindley C, Boj S, Clevers H, Koo B . Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016; 11(9):1724-43. DOI: 10.1038/nprot.2016.097. View

Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L . Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell. 2019; 26(1):17-26.e6. DOI: 10.1016/j.stem.2019.10.010. View

Driehuis E, Spelier S, Hernandez I, de Bree R, Willems S, Clevers H . Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. J Clin Med. 2019; 8(11). PMC: 6912517. DOI: 10.3390/jcm8111880. View

Chhibber T, Bagchi S, Lahooti B, Verma A, Al-Ahmad A, Paul M . CNS organoids: an innovative tool for neurological disease modeling and drug neurotoxicity screening. Drug Discov Today. 2019; 25(2):456-465. PMC: 7039749. DOI: 10.1016/j.drudis.2019.11.010. View

Hill S, Decker B, Roberts E, Horowitz N, Muto M, Worley Jr M . Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018; 8(11):1404-1421. PMC: 6365285. DOI: 10.1158/2159-8290.CD-18-0474. View

Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N . Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Rep. 2019; 27(4):1265-1276.e4. DOI: 10.1016/j.celrep.2019.03.088. View

Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B . Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019; 21(8):1041-1051. DOI: 10.1038/s41556-019-0360-z. View

Yoo S . 3D-printed biological organs: medical potential and patenting opportunity. Expert Opin Ther Pat. 2015; 25(5):507-11. DOI: 10.1517/13543776.2015.1019466. View

10.

Derose Y, Wang G, Lin Y, Bernard P, Buys S, Ebbert M . Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17(11):1514-20. PMC: 3553601. DOI: 10.1038/nm.2454. View

11.

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

12.

Xia X, Li F, He J, Aji R, Gao D . Organoid technology in cancer precision medicine. Cancer Lett. 2019; 457:20-27. DOI: 10.1016/j.canlet.2019.04.039. View

13.

Khoo B, Grenci G, Lim Y, Lee S, Han J, Lim C . Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device. Nat Protoc. 2017; 13(1):34-58. DOI: 10.1038/nprot.2017.125. View

14.

Sharma A, Sances S, Workman M, Svendsen C . Multi-lineage Human iPSC-Derived Platforms for Disease Modeling and Drug Discovery. Cell Stem Cell. 2020; 26(3):309-329. PMC: 7159985. DOI: 10.1016/j.stem.2020.02.011. View

15.

Buzzelli J, Ouaret D, Brown G, Allen P, Muschel R . Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Res. 2018; 27:109-120. PMC: 5842239. DOI: 10.1016/j.scr.2018.01.016. View

16.

Kondo J, Inoue M . Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells. 2019; 8(5). PMC: 6562517. DOI: 10.3390/cells8050470. View

17.

Sontheimer-Phelps A, Hassell B, Ingber D . Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019; 19(2):65-81. DOI: 10.1038/s41568-018-0104-6. View

18.

Yang C, Xia B, Jin W, Lou G . Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int. 2019; 19:341. PMC: 6918690. DOI: 10.1186/s12935-019-1067-8. View

19.

Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R . MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology. 2017; 154(4):1066-1079.e5. PMC: 5863695. DOI: 10.1053/j.gastro.2017.10.043. View

20.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View